chr15-44648976-G-A
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_025137.4(SPG11):c.1492C>T(p.Gln498Ter) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000274 in 1,461,624 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. Q498Q) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_025137.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
SPG11 | NM_025137.4 | c.1492C>T | p.Gln498Ter | stop_gained | 7/40 | ENST00000261866.12 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
SPG11 | ENST00000261866.12 | c.1492C>T | p.Gln498Ter | stop_gained | 7/40 | 1 | NM_025137.4 |
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD3 exomes AF: 0.00000796 AC: 2AN: 251250Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135782
GnomAD4 exome AF: 0.00000274 AC: 4AN: 1461624Hom.: 0 Cov.: 31 AF XY: 0.00000275 AC XY: 2AN XY: 727134
GnomAD4 genome Cov.: 31
ClinVar
Submissions by phenotype
Hereditary spastic paraplegia 11 Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jul 22, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 17, 2023 | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 41399). This premature translational stop signal has been observed in individual(s) with hereditary spastic paraplegia, 24833714 (PMID: 20971220). This variant is present in population databases (rs312262728, gnomAD 0.002%). This sequence change creates a premature translational stop signal (p.Gln498*) in the SPG11 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SPG11 are known to be pathogenic (PMID: 19105190, 20110243, 22154821, 26556829). - |
Pathogenic, criteria provided, single submitter | curation | Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard | Jan 25, 2023 | The homozygous p.Gln498Ter variant in SPG11 was identified by our study in two siblings with spastic paraplegia. The p.Gln498Ter variant in SPG11 has been reported in 2 unrelated individuals with hereditary spastic paraplegia 11 (PMID: 20971220, PMID: 24833714) and segregated with disease in five affected relatives from one family (PMID: 20971220), but has been identified in 0.002% (2/113568) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs312262728). Although this variant has been seen in the general population in a heterozygous state, its frequency is low enough to be consistent with a recessive carrier frequency. Of these 2 unrelated affected individuals (PMID: 20971220, PMID: 24833714), one was a homozygote (PMID: 20971220) and one was a compound heterozygote who carried a likely pathogenic variant in trans (PMID: 24833714, ClinVar Variation ID: 1180685), which increases the likelihood that the p.Gln498Ter variant is pathogenic. This variant has also been reported in ClinVar (Variation ID: 41399) and has been interpreted as pathogenic by the Genome-Nilou Lab, the ‚Äã‚ÄãCeGaT Center for Human Genetics Tuebingen, and GeneReviews. This nonsense variant leads to a premature termination codon at position 498, which is predicted to lead to a truncated or absent protein. Loss of function of the SPG11 gene is an established disease mechanism in autosomal recessive SPG11-related neurologic disease. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive spastic paraplegia 11. ACMG/AMP Criteria applied: PVS1, PM2_Supporting, PM3_Strong, PP1_Moderate (Richards 2015). - |
Pathogenic, no assertion criteria provided | curation | GeneReviews | Jan 31, 2013 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jan 01, 2018 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at